GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Patrys Ltd (ASX:PAB) » Definitions » COGS-to-Revenue

Patrys (ASX:PAB) COGS-to-Revenue : 0.00 (As of Dec. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Patrys COGS-to-Revenue?

Patrys's Cost of Goods Sold for the six months ended in Dec. 2024 was A$0.00 Mil. Its Revenue for the six months ended in Dec. 2024 was A$0.00 Mil.

Patrys's COGS to Revenue for the six months ended in Dec. 2024 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Patrys's Gross Margin % for the six months ended in Dec. 2024 was N/A%.


Patrys COGS-to-Revenue Historical Data

The historical data trend for Patrys's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Patrys COGS-to-Revenue Chart

Patrys Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Patrys Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Patrys COGS-to-Revenue Calculation

Patrys's COGS to Revenue for the fiscal year that ended in Jun. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0 / 0
=

Patrys's COGS to Revenue for the quarter that ended in Dec. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0 / 0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Patrys  (ASX:PAB) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Patrys's Gross Margin % for the six months ended in Dec. 2024 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 0 / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Patrys COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Patrys's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Patrys Business Description

Traded in Other Exchanges
N/A
Address
Level 4, 100 Albert Road, South Melbourne, Melbourne, VIC, AUS, 3205
Patrys Ltd focuses on the development of natural human antibody-based therapies for the treatment of cancer. The company's product includes Deoxymab 3E10, PAT-SC1, PAT-DX1 PAT-DX1-NP, PAT-DX3, and PAT-LM1. Its main technology is Deoxymab 3E10, a DNA damage repair (DDR) antibody that penetrates live cell nuclei and inhibits key mechanisms of DNA repair in target cancer cells.

Patrys Headlines